The current disruption shows supply chains are not abstract systems, but physical networks, dependent on specific routes, materials & decisions.
Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses.
Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Boehringer has altered the terms of its digital therapeutic alliance with Click on schizophrenia app CT-155, taking a more strategic investor role.
AbbVie has opened a new front in the pharma industry's efforts to reform the 340B drug discounting programme for safety net hospitals in the US.
Editor's Picks
